This article explains why some technologies may fail to demonstrate cost effectiveness even when the acquisition price is set to zero, raising both methodological and ethical questions for health technology assessment (HTA) agencies. Learn more here. (Source: Sarah Davis, Dr. Ron Akehurst, Health Policy)
You are here: Home / Cost Effectiveness / Evaluating Technologies Found Cost Effective at Zero Price